Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2011

View Archived Issues

Genus Oncology's GO-203-2c enters phase I trial in solid tumors

Mutant EPO lacking erythropoietic activity protects against ischemic brain injury

Modified mRNA molecules could be alternatives to DNA-based therapies

Regulating adenosine signaling improves symptoms of sickle cell disease

Programmable bio-nano-chips offer rapid and low-cost biomarker analysis

Creatine kinase levels predict hemorrhagic transformation in patients receiving alteplase for stroke

BPX-101 shows promise in phase I/II trial in metastatic prostate cancer

Tibotec begins recruitment in phase III trials of HCV protease inhibitor TMC-435

Novel renin inhibitors discovered at sanofi-aventis

Roche patents new activators of glucokinase

New inhibitors claimed of cGMP-dependent 3',5'-cyclic phosphodiesterase

Amgen reviews highlights of fourth quarter 2010

Vitae Pharmaceuticals claims new 11-beta-HSD1 inhibitors

UCSD clears Stemedica's phase I/II trial of allogeneic stem cells for stroke

Eisai divulges novel beta-secretase 1 inhibitors

Micell Technologies enrolls first patient in DESSOLVE-II trial of MiStent DES

Spanish scientists identify novel phenalenones with cytotoxic effects

Merck Serono Europe withdraws MAA for Movectro

EMA's CHMP recommends approval of Hizentra

Conatus Pharma begins phase II trial of CTS-1027 in hepatitis C

BioDelivery Sciences on track with phase III trial of BEMA Buprenorphine in chronic pain

Apricus Bio and FDA discuss SPA for phase III PrevOnco trial

Cytos obtains E.U. funding to help develop vaccines against emerging viral diseases

Antisense Therapeutics begins final preparations for first clinical trial of ATL-1103

FDA approves Corifact for prophylactic treatment of congenital coagulation factor XIII deficiency

CHMP issues positive opinion on Novartis' Rasilamlo for high blood pressure

Intercell's JE vaccine enters pivotal phase II/III pediatric trial in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...